05th week of 2012 patent applcation highlights part 42 |
Patent application number | Title | Published |
20120027738 | MATERNAL SUPPLEMENT - The use of docosahexaenoic acid in the manufacture of a composition for administration to a pregnant woman for reducing the risk of development of overweight or obesity of the baby in infancy and/or early childhood. | 2012-02-02 |
20120027739 | T CELL RECEPTORS - A T cell receptor (TCR) having the property of binding to EVDPIGHLY HLA-A1 complex and comprising a specified wild type TCR which has specific mutations in the TCR alpha variable domain and/or the TCR beta variable domain to increase affinity. Such TCRs are useful for adoptive therapy. | 2012-02-02 |
20120027740 | METHOD AND MEANS FOR PRODUCING TISSUES AND TISSUES OBTAINED - A method regenerates specific tissue, preferably mesenchymal tissues like bone, fat, tendon, muscle, cartilage and marrow stroma and hematological tissue (RBC, WBC, platelets, lymphocytes, hematological stem cells (HSC), endothelial progenitor cells (EPC) etc.). A method for reconstructing, regenerating, rejuvenating or reinforcing a damaged or diseased tissue in a mammal subject, and preferably a human patient, uses a (regenerated) tissue obtained by this method. | 2012-02-02 |
20120027741 | PESTICIDE COMPOSITION COMPRISING A TETRAZOLYLOXIME DERIVATIVE AND A FUNGICIDE OR AN INSECTICIDE ACTIVE SUBSTANCE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative and a fungicide or an insecticide active substance or compound. | 2012-02-02 |
20120027742 | METHODS FOR TREATING ADULT RESPIRATORY DISTRESS SYNDROME - We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS. | 2012-02-02 |
20120027743 | Method for the Treatment of Hemophilia - The present invention is directed to a method for the treatment of hemophilia. | 2012-02-02 |
20120027744 | MODIFIED HEPARINASE III AND METHODS OF SEQUENCING THEREWITH - The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs. | 2012-02-02 |
20120027745 | ALANINE-GLYOXYLATE AMINOTRANSFERASE THERAPEUTICS - The present invention relates to an alanine glyoxylate aminotransferase (AGXT) I340M therapeutic for use as a medicament or in a method of treatment, for example in the treatment of an AGXT-responsive condition. The AGXT I340M therapeutic is an AGXT I340M protein comprising an amino acid sequence, which, when optimally aligned with SEQ ID NO: 2, comprises a methionine at a position corresponding to position 340 in SEQ ID NO: 2, a nucleic acid molecule encoding such an AGXT I340M protein, or a virion of a viral gene therapy vector comprising such a nucleic acid molecule. The AGXT I340M therapeutic has a higher specific activity as compared to other AGXT alleles and may therefore be advantageously used in the treatment of primary hyperoxaluria type I. | 2012-02-02 |
20120027746 | METHOD FOR GENERATING THROMBIN - Methods of generating thrombin and methods of applying a clotting tissue sealant to a site on a subject are provided. A blood component comprising platelets can be obtained from the subject. A hypotonic composition is contacted with a solid matrix to form a thrombin-containing liquid, where the hypotonic composition includes water, calcium, a blood component comprising platelets, and optionally a chelator. Calcium is present in the hypotonic composition in an amount greater than the amount of calcium that can be complexed by the chelator. Thrombin-containing liquid is then separated from the hypotonic composition and can be applied to the site on the subject to form a clot, for example, by combination with fibrinogen. | 2012-02-02 |
20120027747 | Compositions and methods for mycotoxin decontamination of animal feed, food, soil and plants using biomass of filamentous fungi and its selected components - A method of rendering harmless mycotoxins contaminating food, animal feed and assisting infection of plant hosts by microbial parasites is proposed. The method comprises binding mycotoxins by a novel adsorbent, consisting partially or in full of the biomass of filamentous fungi or isolated fungal biomass components, such as chitin, chitozan and hyrdophobins, or fungal biomass enriched in its capacity to bind said mycotoxins using fungal species and strain selection, genetic engineering of fungi, modification of fungal fermentation conditions and downstream physical and chemical treatment of fungal biomass, such as milling or micronization in a dry state. The resulting adsorbent can bind a wide range of mycotoxins, including the ones difficult to bind (Ochratoxin, T-2, DON, NIV) using a current generation of mycotoxin adsorbents based on clay, resins, yeast and bacterial biomass. The adsorbent can be used as an animal feed additive, functional food additive and agricultural fungistatic/fungicide. | 2012-02-02 |
20120027748 | IMMUNOLOGICAL RECONSTITUTION PROMOTER OR PROPHYLACTIC AGENT FOR INFECTIONS EACH OF WHICH MAINTAINS GRAFT-VERSUS-TUMOR EFFECT - The object of the invention is to provide an immunological reconstitution promoter or a prophylactic agent for infections for use in allogeneic hematopoietic stem cell transplantation therapy for tumors. The promoter or prophylactic agent enables the amelioration of delayed immune reconstitution or the prevention of infection following transplantation, while maintaining the GVT effect of allogeneic hematopoietic stem cell transplantation. Specifically, in a transplant patient in whom immune reconstitution is delayed, such reconstitution can be promoted by administering, at an early stage following transplantation, a substance capable of depleting CD4 | 2012-02-02 |
20120027749 | Method - The present invention provides a method for detecting a 5T4-positive cancer in a subject, which comprises the following steps: (i) identifying and/or isolating exosomes in a sample from the subject; and (ii) detecting exosome-associated 5T4. | 2012-02-02 |
20120027750 | METHOD AND COMPOSITIONS FOR CANCER PROGNOSIS - Methods are provided to determine the cancer prognosis of subjects and/or to adapt the treatment protocol of subjects having or susceptible to cancer. Embodiments include the steps of determining in vitro the genotype of said subject at a polymorphism in the C3-ITGAM axis, making a cancer prognosis of the subject based on said genotype and selecting an anti-cancer treatment for the subject. | 2012-02-02 |
20120027751 | ANTAGONISTS OF TWEAK AND OF TWEAK RECEPTOR AND THEIR USE TO TREAT IMMUNOLOGICAL DISORDERS - The present invention relates to reagents which modify the activity of TWEAK and their use as therapeutic agents for the treatment of immunological disorders. | 2012-02-02 |
20120027752 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS - Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: | 2012-02-02 |
20120027753 | MicroRNAs in Never-Smokers and Related Materials and Methods - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of lung cancer in never-smokers. The invention also provides methods of identifying anti-lung cancer agents. | 2012-02-02 |
20120027754 | Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6 - The present invention relates to methods of asthma treatment and prevention using α | 2012-02-02 |
20120027755 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The invention relates to a purified antibody or fragment thereof that specifically binds an Aβ protofibril. The invention further relates to a composition that includes such antibodies. The invention also relates to using such antibodies and compositions for treating a patient having of suspected of having Alzheimer's disease. | 2012-02-02 |
20120027756 | METHODS AND COMPOSITIONS FOR TREATING ALLERGIC DISEASES - Disclosed in the present invention are antibodies that specifically recognize and antagonize human TSLP receptor, and methods of employing these antibodies to treat or ameliorate diseases or disorder mediated by TSLP signaling. | 2012-02-02 |
20120027757 | COMPOSITIONS AND METHODS FOR TREATING CANCER - A method of treating a cancer with an mTOR inhibitor and an anti-IGF-1 R antibody is disclosed. | 2012-02-02 |
20120027758 | USE OF ANTI-CD100 ANTIBODIES - The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells. | 2012-02-02 |
20120027759 | METHODS OF ENHANCING T CELL RESPONSIVENESS - The invention features methods of enhancing the responsiveness of a T cell. Such methods involve interfering with the interaction between a T cell and a B7-H1 molecule. | 2012-02-02 |
20120027760 | ADIPONECTIN RECEPTOR AND GENE ENCODING THE SAME - The object is to isolate and identify human and mouse adiponectin receptors, to provide a novel protein having adiponectin binding ability, and to provide a screening method and screening kit for a ligand, agonist and antagonist to an adiponectin receptor using such protein. To achieve this object, a protein is used, as novel protein having adiponectin binding ability, that is (a) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8, or (b) a protein comprising an amino acid sequence according to Seq. No. 2, 4, 6 or 8 with one or more amino acids deleted, replaced or added, and having adiponectin binding ability. | 2012-02-02 |
20120027761 | Treatment of Inflammatory Diseases by Inhibiting Cold-Inducible RNA-Binding Protein (CIRP) - Disclosed are pharmaceutical compositions comprising a CIRP inhibitor. A method of treating a subject suffering from an inflammatory condition comprising administering to said subject a CIRP inhibitor is also described herein. | 2012-02-02 |
20120027762 | IMMUNOGENIC COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF - The present invention relates to a method of inducing an immune response to a parasite utilizing an immunogenic composition comprising a glycosylphosphatidylinositol (“GPI”) inositolglycan domain or its derivative or equivalent. The present invention is useful as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as parasite infections and particularly infection by | 2012-02-02 |
20120027763 | Antibody for Targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1 - Antibody for targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1, is disclosed. The antibodies, TBL-CLN1, are monoclonal antibodies which can specifically target and bind to the epitope of SEQ ID NO:1 expressed on cancer cells which further leads to killing of cancer cells. TBL-CLN1 is not conjugated to toxin or cytotoxic molecules, and provides selective killing of cancer cells just by binding to cancer cell surface. Also, disclosed herein is SEQ ID NO: 2 which is an engineered epitope which comprises of polypeptide sequence of SEQ ID NO: 1 and a cysteine residue which is added at the carboxyl end of the SEQ ID NO: 1. The epitope of SEQ ID NO: 2 is used to generate monoclonal antibodies described herein. | 2012-02-02 |
20120027764 | NOVEL POLYPEPTIDE, CDNA ENCODING THE SAME, AND USE THEREOF - Novel polypeptides produced by a human adult brain tissue, a cell line derived therefrom, a cell line derived from human bone marrow and a human umbilical cord venous endothelial cell line; a process for producing these polypeptides; cDNAs encoding the polypeptides; fragments hybridizable selectively with the cDNA sequences; replication or expression plasmids having the cDNAs integrated thereinto; host cells transformed by the plasmids; antibodies against the above polypeptides; and medicinal compositions containing the peptides or the antibodies. | 2012-02-02 |
20120027765 | ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9) - Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described. | 2012-02-02 |
20120027766 | METHODS AND MEANS FOR TREATMENT OF OSTEOARTHRITIS - The invention relates to the field of medicinal research, cartilage physiology and diseases involving the degeneration of cartilage tissue. More specifically, the invention relates to methods and means for identifying compounds that inhibit catabolic processes in chondrocytes and that decrease the degradation of cartilage and/or ECM. The invention also relates to the compounds that are useful in the treatment of osteoarthritis. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and/or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and/or cartilage and inflammation. | 2012-02-02 |
20120027767 | ANTIBODIES AGAINST PDGFR ALPHA TO INHIBIT TUMOR GROWTH - The invention provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides methods for neutralizing activation of PDGFRα and a methods of treating a mammal with a neoplastic disease using the antibodies alone or in combination with other agents. | 2012-02-02 |
20120027768 | MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS - A method for producing a clone of an immortalised human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalised human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Ban virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalised human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity. | 2012-02-02 |
20120027769 | ANTI-RHD MONOCLONAL ANTIBODIES - Anti-RhD monoclonal antibodies and methods for the production thereof. | 2012-02-02 |
20120027770 | NOVEL CELL AND THERAPEUTICAL AND DIAGNOSTICAL METHODS BASED THEREON - The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman. | 2012-02-02 |
20120027771 | AFFINITY PURIFIED HUMAN POLYCLONAL ANTIBODIES AGAINST VIRAL, BACTERIAL AND/OR FUNGAL INFECTIONS AND METHODS OF MAKING AND USING THE SAME - The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified from human blood using certain viral, bacterial, eukaryotic protist and/or fungal antigens as described herein. Methods of making the antigenic preparations and the affinity-purified human polyclonal antibodies for passive immunization are also provided. | 2012-02-02 |
20120027772 | THERAPEUTIC PROTEIN FORMULATIONS - The present invention generally concerns formulations having a pH that inhibits aspartyl isomerization at an Asp-Asp motif in a therapeutic protein contained in such a formulation. | 2012-02-02 |
20120027773 | ANTI-RON ANTIBODIES - Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON. | 2012-02-02 |
20120027774 | METALLOPROTEINASE 9 BINDING PROTEINS - Proteins that bind to matrix metalloproteinase 9 and methods of using such proteins are described. | 2012-02-02 |
20120027775 | ABSORBABLE PEG-BASED HYDROGELS - An absorbable PEG-based hydrogel prepared from a multi-arm-PEG-vinylsulfone having about 3 to about 8 arms and a multi-arm-PEG-R-sulfhydryl having about 3 to about 8 arms; where R is defined as an ester linkage, such as carboxylate ester, lactate ester, and isobutyrate ester have been disclosed. Additionally, sustained release compositions that are prepared from an absorbable PEG-based hydrogel and a protein have been disclosed which provide sustained release of proteins and peptides. | 2012-02-02 |
20120027776 | DIABETIC MODEL - An isolated nucleic acid molecule is disclosed, including a nucleotide sequence selected from the nucleotide sequence of (a) Ljungan virus 87-012, (b) Ljungan virus 145SL, (c) Ljungan virus 174F, and (d) a fragment of nucleotide sequences (a)-(c). Also disclosed are polypeptides encoded by the isolated nucleic acid, which are useful in preparing vaccines and antibodies to prevent or inhibit conditions caused by Ljungan virus, including diabetes. | 2012-02-02 |
20120027777 | LJUNGAN VIRUS WITH IMPROVED REPLICATION CHARACTERISTICS - The present invention relates to a Ljungan virus with improved replication characteristic and the use of this Ljungan virus, amongst other thing, in the production of a vaccine. | 2012-02-02 |
20120027778 | Frizzled-Binding Agents and Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided. | 2012-02-02 |
20120027779 | Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers - The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment. | 2012-02-02 |
20120027780 | ANTICOAGULANT ANTIDOTES - The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants. | 2012-02-02 |
20120027781 | Neuroprotective and neurorestorative method and compositions - The invention relates to methods and products for preventing and treating neuronal cell death-associated diseases and/or conditions. The products and methods are useful for research and for clinical applications relating to neuronal cell-death associated diseases and/or conditions. | 2012-02-02 |
20120027782 | MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) - The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates. | 2012-02-02 |
20120027783 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-02-02 |
20120027784 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS - Auristatin peptides, including MeVal-Val-Dil-Dap-Norephedrine (MMAE) and MeVal-Val-Dil-Dap-Phe (MMAF), were prepared and attached to Ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo. | 2012-02-02 |
20120027785 | CHIMERA COMPRISING BACTERIAL CYTOTOXIN AND METHODS OF USING THE SAME - This invention provides, a recombinant polypeptide encoding a chimera. The chimera includes a DNase I fragment or a homologue thereof and a Cdt fragment or a homologue thereof. Further, the invention provides methods, utilizing the recombinant polypeptide encoding the chimera, such as a method for inhibiting the proliferation of a neoplastic cell, a method for treating a neoplastic disease in a human subject, a method for inhibiting or suppressing a neoplastic disease in a human subject, and a method for reducing the symptoms associated with a neoplastic disease in a human subject. | 2012-02-02 |
20120027786 | GENETICALLY PROGRAMMABLE PATHOGEN SENSE AND DESTROY - Aspects of the invention relate to compositions and methods for using recombinant cells to sense and destroy specific pathogens. | 2012-02-02 |
20120027787 | PLANT DERIVED SEED EXTRACT RICH IN ESSENTIAL FATTY ACIDS DERIVED FROM PERILLA SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE - A composition of matter comprises a shelf stable, super critical, CO | 2012-02-02 |
20120027788 | SIMIAN ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF - The present invention relates to novel adenovirus strains with an improved sero-prevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polynucleotides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease. | 2012-02-02 |
20120027789 | ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAME - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV, The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2012-02-02 |
20120027790 | IMMUNOLOGICAL HERPES SIMPLEX VIRUS ANTIGENS AND METHODS FOR USE THEREOF - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 2012-02-02 |
20120027791 | ANTISENSE COMPOUND FOR INDUCING IMMUNOLOGICAL TOLERANCE - A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions. | 2012-02-02 |
20120027792 | EXPRESSION VECTORS ABLE TO ELICIT IMPROVED IMMUNE RESPONSE AND METHODS OF USING SAME - The invention relates to nucleic acids (such as DNA immunization plasmids), encoding fusion proteins containing a destabilizing amino acid sequence attached to an amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased by the presence of the destabilizing amino acid sequence. The invention also relates to nucleic acids encoding secreted fusion proteins, such as those containing chemokines or cytokines, and an attached amino acid sequence of interest, in which the immunogenicity of the amino acid sequence of interest is increased as a result of being attached to the secretory sequence. The invention also relates methods of increasing the immunogenicity of the encoded proteins for use as vaccines or in gene therapy. | 2012-02-02 |
20120027793 | COMPOSITIONS COMPRISING CHLAMYDIA ANTIGENS - There is provided a composition for inducing an immune response to a | 2012-02-02 |
20120027794 | TUBERCULOSIS VACCINE WITH IMPROVED EFFICACY - The present invention relates to novel recombinant vaccines providing protective immunity against tuberculosis. Further, the present invention refers to novel recombinant nucleic acid molecules, vectors containing said nucleic acid molecules, cells transformed with said nucleic acid molecules and polypeptides encoded by said nucleic acid molecules. | 2012-02-02 |
20120027795 | SIMPLE VACCINES FROM DNA LAUNCHED SUICIDAL FLAVIVIRUSES - Immunogenic compositions relating to DNA launched suicidal flaviviruses and methods of administering the same are described herein. | 2012-02-02 |
20120027796 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)). | 2012-02-02 |
20120027797 | Preservation of Bioactive Materials by Freeze Dried Foam - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. | 2012-02-02 |
20120027798 | ANTIBODY GENE TRANSFER AND RECOMBINANT AAV THEREFOR - The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified. | 2012-02-02 |
20120027799 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY BOWEL DISEASE AND COLON CANCER - The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease). | 2012-02-02 |
20120027800 | NEISSERIAL VACCINE COMPOSITIONS COMPRISING A COMBINATION OF ANTIGENS - The present invention relates to immunogenic compositions and vaccines for the treatment and prevention of Neisserial disease. Immunogenic compositions of the invention contain combinations of antigens selected from at least two different classes of antigens including adhesins, autotransporter proteins, toxins, iron acquisitions proteins and membrane-associated protein (preferably integral outer membrane protein)s. Such combinations of antigens are able to target the immune response against different aspects of the neisserial life cycle, resulting in a more effective immune response. | 2012-02-02 |
20120027801 | POLYPEPTIDES FROM NEISSERIA MENINGITIDIS - Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis. | 2012-02-02 |
20120027802 | USE OF COMMON GAMMA CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES - It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed. | 2012-02-02 |
20120027803 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS - The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid. | 2012-02-02 |
20120027804 | MEDICAL PRODUCT, IN PARTICULAR FOR MANAGEMENT OF TISSUE REPAIR - A medical product includes at least one elongate body including cells and a method for manufacturing the medical product. | 2012-02-02 |
20120027805 | Controlled-Released Peptide Formulations - Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent. | 2012-02-02 |
20120027806 | DOSE SELECTION OF ADJUVANTED SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods. | 2012-02-02 |
20120027807 | TISSUE ENGINEERED MYOCARDIUM AND METHODS OF PRODUCTION AND USES THEREOF - The present invention generally relates to a population of committed ventricular progenitor (CVP) cells and their use to generate a tissue engineered myocardium, in particular two dimensional tissue engineered myocardium which is comparable to functional ventricular heart muscle. One embodiment of present invention provides a composition and methods for the production of a tissue engineered myocardium which has functional properties of cardiac muscle, such as contractibility (e.g. contraction force) and numerous properties of mature fully functional ventricular heart muscle tissue. In particular, in one embodiment, a composition comprising the tissue engineered myocardium comprises committed ventricular progenitor (CVP) cells seeded on a free-standing biopolymer structure to form functional ventricular myocardium tissue. | 2012-02-02 |
20120027808 | NICOTINE IMMUNONANOTHERAPEUTICS - The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies. | 2012-02-02 |
20120027809 | Pharmaceutical compositions comprising water-soluble sulfonate-protected nanoparticles and uses thereof - The present invention provides pharmaceutical compositions comprising water-soluble sulfonate-protected nanoparticles, more particularly, pharmaceutical compositions comprising water-soluble sulfonate-protected silver or gold nanoparticles. The pharmaceutical compositions of the invention are useful in prevention or treatment of infections or conditions or disorders caused by microorganisms capable of binding to heparan sulfate, e.g., herpes simplex viruses. | 2012-02-02 |
20120027810 | PATCH PRODUCTION - A method for use in producing a patch having a number of projections thereon. The method includes providing a distribution member and filling material on a mold surface, the mold including a number of cavities extending from the mold surface for defining the patch projections, filling the cavities with filling material, at least in part by urging filling material from the distribution member into the cavities, causing the filling material to solidify and separating the solidified filling material and the mold to thereby form the patch. | 2012-02-02 |
20120027811 | Formulations of Viable Cells for Oral Delivery - This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine. | 2012-02-02 |
20120027812 | INTRAOCULAR LENSES TREATED WITH ALKYLPHOSPHOCHOLINES FOR PHARMACOLOGICAL AFTERCATARACT PROPHYLAXIS - The invention relates to ophthalmological implants which comprise alkylphosphocholines. Implants of this type may in particular advantageously be used for the prophylaxis of aftercataract. | 2012-02-02 |
20120027813 | ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE - An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus. | 2012-02-02 |
20120027814 | Polymeric Fibers Having Tissue Reactive Members - A method for bonding a polymeric fiber to tissue is provided which includes providing a polymeric fiber having a plurality of tissue reactive members linked to a surface of the fiber via a specific binding pair, and contacting the polymeric fiber to biological tissue, to covalently bond the fiber to the tissue. | 2012-02-02 |
20120027816 | HIGHLY PURE ELETRIPTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF ELETRIPTAN N-OXIDE IMPURITY - Provided herein is an impurity of eletriptan, eletriptan N-oxide, (R)-5-[2- (phenylsulfonypethyl]-3-[(1-methyl-2-pyrrolidinyl-N-oxide)methyl]-1H-indole, and a process for the preparation and isolation thereof. Provided further herein is a highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan N-oxide impurity, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure eletriptan or a pharmaceutically acceptable salt thereof substantially free of eletriptan N-oxide impurity. | 2012-02-02 |
20120027817 | Absorbable Implants and Methods for Their Use in Hemostasis - The present invention relates to mechanically hemostatic body-absorbable compositions having a putty-like consistency comprising a finely powdered polysaccharide and a biocompatible liquid comprising one or more block copolymers of ethylene oxide and propylene oxide. | 2012-02-02 |
20120027818 | BISPHOSPHONATE PRODUCT IN A CYCLOOLEFINIC POLYMER CONTAINER - A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment. | 2012-02-02 |
20120027819 | Medical Devices Incorporating a Bioactive and Methods of Preparing Such Devices - One embodiment provides a medical device comprising a base material and a bioactive in contact with the base material, the bioactive having a proton binding site with a non-ionic form and an ionic form, the bioactive being less soluble in water when the proton binding site is in the non-ionic form than when the proton binding site is in the ionic form, wherein at least 5% w/w of the bioactive is present with the proton binding site in the non-ionic form and wherein the bioactive is not an anesthetic. Another embodiment provides such a medical device where the bioactive is an anesthetic and where the device is not a ureteral stent. Another aspect provides method of manufacturing such devices. | 2012-02-02 |
20120027820 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 2012-02-02 |
20120027821 | AMINO ACID-CONJUGATED CYANOACRYLATE POLYMER PARTICLES - Disclosed are cyanoacrylate polymer particles which comprise an amino acid(s) and have an average particle diameter of less than | 2012-02-02 |
20120027822 | Process for Producing Rapidly Disintegrating Spheroids (Pellets), Granules and/or Mixtures Thereof - Process for producing rapidly disintegrating spheroids (pellets), granules and/or mixtures thereof, which disintegrate in less than 15 minutes. The spheroids comprise at least one active pharmaceutical ingredient, a spheronizing aid material and a solid Polyethylene glycol (PEG) with mean molecular weight (MW) of over 1,000. The process comprises a direct pelletization step in a fluidized bed rotogranulator, using aqueous binding media whilst the temperature of the process does not exceed the melting point of the solid PEG. | 2012-02-02 |
20120027823 | METHODS OF TREATMENT USING A GASTRIC RETAINED GABAPENTIN DOSAGE - A method of treatment for epilepsy and other disease states is described, which comprises delivery of gabapentin in a gastric retained dosage form. | 2012-02-02 |
20120027824 | Preparations facilitated by vesicles using alkyl polypentosides and uses of said preparations - Surfactant system capable of forming a dispersion of vesicles or liposomes constituted of alkyl polyglycoside of formula RO(X)n, in which R is a linear or branched alkyl chain, with or without unsaturation, and having 8 to 12 carbon atoms, X being a pentose residue, and n, representing the average degree of oligomerization, is between 1 and 3, and of a hydrotrope or co-solvent. | 2012-02-02 |
20120027825 | METHOD OF PREPARING LIPID NANOPARTICLES - The present invention relates to a useful method for preparing nanocapsules having a liquid lipid core and a solid shell and charged with at least one active agent having a hydrophilic character, said method comprising at least the steps consisting in: i) providing at least a first microemulsion having a water-in-oil character, stabilized by at least one lipophilic surfactant and containing in its hydrophilic phase at least one active agent having a hydrophilic character, providing at least a second microemulsion, separate from the first microemulsion, formulated by phase inversion of an emulsion and stabilized by at least one heat-sensitive, nonionic hydrophilic surfactant; iii) adding said first microemulsion to said second microemulsion under conditions propitious for the formation of a novel microemulsion architecture in which said hydrophilic active agent remains present in the hydrophilic phase of the first microemulsion; and iv) chill-hardening the mixture formed in the previous step, so as to obtain nanocapsules comprising said hydrophilic active agent and being formed from a lipid core, which is liquid at room temperature, and encapsulated in a film which is solid at room temperature. | 2012-02-02 |
20120027826 | Free-Flowing Emulsion Concentrates - Emulsion concentrates comprising at least one alkyl and/or alkenyl oligoglycoside having 6 to 22 carbon atoms in the alk(en)yl radical, polyglycerol esters, at least one polyol, at least one glyceride having a melting point greater than or equal to 20° C., at least one oil component liquid at 20° C. and with a polarity of more than 30-40 mN/m and at least one oil component liquid at 20° C. and with a polarity of 5-30 mN/m are described. Methods of making and using such emulsion concentrates are also described. Articles employing the emulsion concentrates are also described. | 2012-02-02 |
20120027827 | Method and Composition for Reducing Exhaled Carbon Dioxide Emissions - A method and composition for reducing the amount of carbon dioxide exhaled by a user by placing a composition comprising a delivery vehicle and a carbon dioxide sequestering agent into a user's mouth and allowing the carbon dioxide sequestering agent to react with the carbon dioxide present in the user's breath thereby reducing the amount of carbon dioxide exhaled by the user. | 2012-02-02 |
20120027828 | Dental anti-hypersensitivity composition and method - The present invention relates to compositions and methods for calcifying dental tissue, e.g., preventing or treating dental hypersensitivity. An oral composition of arginine bicarbonate and calcium carbonate promotes the formation of dentinal tubule plugs aided by combining calcium and phosphate in the fluid. In a specific example, an arginine bicarbonate/calcium carbonate mixture blocked dentinal tubules in a model system. In addition to treating dentinal sensitivity, the compositions and methods of the invention provide for calcifying exposed tooth pulp, calcifying the base or all of a pit or fissure in a tooth, and treating a carious lesion. | 2012-02-02 |
20120027829 | DENTIN MINERALIZING AGENT AND METHOD FOR PRODUCTION THEREOF - A dentin mineralizing agent comprising tetracalcium phosphate particles (A) and an alkali metal salt of phosphoric acid (B), wherein the dentin mineralizing agent contains the tetracalcium phosphate particles (A) in an amount of 1 to 80 parts by weight relative to 100 parts by weight of the whole amount of the dentin mineralizing agent, and the blended amount of the alkali metal salt of phosphoric acid (B) relative to 100 parts by weight of the tetracalcium phosphate particles (A) is 1 to 100 parts by weight. Thus is provided a dentin mineralizing agent by which a dense HAp is formed on a dentin surface and HAp is deposited to a deep portion of a dentinal tubule, so that it can close the dentinal tubule. | 2012-02-02 |
20120027830 | COSMETIC - The present invention provides a cosmetic composition comprising composite powder grains including: metal oxide flakes having an average thickness in a range of from 50 nm to 200 nm and an aspect ratio in a range of from 10 to 1000; and a coating layer which coat a surface of the metal oxide flakes, and which has a higher refractive index than that of the metal oxide flakes. | 2012-02-02 |
20120027831 | DEPOSITION FROM SURFACTANT SYSTEMS - The invention presented in this application relates to a fragrance deposition system for high surfactant applications such as shampoo and body wash. The system will provide a long lasting release of the fragrance and is more efficient at low levels and does not deposit particles that can cause adverse properties. | 2012-02-02 |
20120027832 | USE OF EDDS AND CALCIUM IONS AS ENHANCERS OF MOLLUSCICIDAL ACTIVITY - A molluscicidal composition, comprising: a molluscicide; a molluscicidal activity promoting additive comprising a calcium-containing salt of ethylene disuccinic acid or calcium ions and ethylenediamine disuccinic moieties, having at least 1 mole of calcium per mole of ethylenediamine disuccinic acid; and a carrier material edible to molluscs. | 2012-02-02 |
20120027833 | DRUG-ELUTING FILMS - Polymeric porous films, capable of eluding a bioactive agent when coming in contact with a physiological medium according to a pre-determined and controlled release profile suitable for particular type of drug and indication, and medical devices including the same are disclosed. Also disclosed are processes for producing the polymeric porous films by freeze-drying an inverted emulsion formulation in which the polymer's composition, the polymer's concentration, the polymer's initial molecular weight, the concentration and/or the type of a surfactant, the homogenization rate and/or the oil phase to aqueous phase ratio (O:A) are selected so as to impart a desired release profile of the bioactive agent from the polymeric film. | 2012-02-02 |
20120027834 | METHODS OF TREATMENT WITH SYK INHIBITORS - The present invention provides novel compositions and methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient undergoing a vascular intervention. More particularly, the present invention provides intravascular devices coated with one or more spleen tyrosine kinase (Syk) inhibitors. Methods for inhibiting restenosis, thrombosis, and/or inflammation in a patient by treatment with such intravascular devices are also provided. In addition, the present invention provides methods for treating sickle cell disease using Syk inhibitors. | 2012-02-02 |
20120027835 | SURGICAL PROSTHESIS HAVING BIODEGRADABLE AND NONBIODEGRADABLE REGIONS - A prosthesis for repairing a hernia includes an adhesion-resistant biodegradable region and an opposing tissue-ingrowth biodegradable region. When the prosthesis is implanted into the patient, the adhesion-resistant biodegradable region covers a fascial defect of the hernia, and the tissue-ingrowth biodegradable region is located above the adhesion-resistant biodegradable region while being exposed substantially only to the hoses subcutaneous tissue layer. This orientation allows the tissue-ingrowth biodegradable region to become firmly incorporated with the host's body tissue. The adhesion-resistant biodegradable region faces the internal organs and decreases the incidence of adhesions and/or bowel obstruction. | 2012-02-02 |
20120027836 | NOVEL EDWARDSIELLA ICTALURI E-ICT-VL33 STRAIN, VACCINES THEREOF, AND A METHOD FOR PROTECTING FISHES USING SAID VACCINES | 2012-02-02 |
20120027837 | MULTILAYER COATING COMPOSITIONS, COATED SUBSTRATES AND METHODS THEREOF - The present invention provides, among other things, multilayer film coating compositions, coated substrates and methods thereof In some embodiments, a structure, comprising a substrate and a multilayer film on the substrate, wherein the multilayer film comprises a first plurality of first units, each first unit comprising a protamine polypeptide. In some embodiments, a structure comprising a microneedle substrate and a multilayer film coated on at least portion of the microneedle substrate, wherein the multilayer film comprises an agent for release and a first plurality of first unit; each first unit comprising a first layer and a second layer, wherein the first layer and the second layer are associated with one another. | 2012-02-02 |
20120027838 | FILAMENTS COMPRISING AN INGESTIBLE ACTIVE AGENT NONWOVEN WEBS AND METHODS FOR MAKING SAME - Filaments containing a filament-forming material and an additive, such as an ingestible active agent, nonwoven webs, and methods for making such filaments are provided. | 2012-02-02 |